- Psyched Wellness (PSYC) plans to launch its Amanita Muscaria (AME-1) products in the U.S. in Q2 2022
- The company’s products will undergo regulatory analysis in both Canada and the U.S.
- These processes will allow for sales across conventional food, dietary supplement and natural health product categories
- Psyched Wellness is a health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods
- Psyched Wellness (PSYC) is up by 9.09 per cent and is currently trading at $0.12 per share
Psyched Wellness (PSYC) plans to launch its Amanita Muscaria products in the U.S. in Q2 2022.
The company is having a self-generally recognized as safe dossier reviewed by an external panel of experts. The process permits substances to be exempted from premarket review by the F.D.A.
It also plans to submit to Health Canada for a natural health product number.
These regulatory processes will allow Psyched to sell in multiple categories including U.S. conventional foods, U.S. dietary supplements and Canadian natural health products.
The company is working closely with KGK Science to apply for all requisite approvals.
“This is an important and logical step forward as we pursue our strategy to create premium Amanita Muscaria mushroom-derived products and become a leading North American brand in the emerging functional food category,” said Jeff Stevens, CEO of Psyched Wellness.
Psyched Wellness is a health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods.
Psyched Wellness (PSYC) is up by 9.09 per cent and is currently trading at $0.12 per share as of 11:07 am EST.
